RNAZ Files 8-K on Shareholder Vote Submission
Ticker: RNAZ · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1829635
Complexity: simple
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, 8-K
TL;DR
**RNAZ just filed an 8-K about a shareholder vote, keep an eye out for details on what they voted on.**
AI Summary
Transcode Therapeutics, Inc. (RNAZ) filed an 8-K on January 8, 2024, indicating a 'Submission of Matters to a Vote of Security Holders.' This filing is a procedural update, likely related to a shareholder vote that occurred or is pending, as it also mentions 'Written communications pursuant to Rule 425 under the Securities Act.' For investors, this matters because shareholder votes often involve significant corporate actions like stock issuances, mergers, or changes to company bylaws, which can directly impact share value and ownership dilution.
Why It Matters
This filing signals that Transcode Therapeutics is engaging with its shareholders on a specific matter, which could lead to changes affecting the company's capital structure or strategic direction.
Risk Assessment
Risk Level: medium — The risk is medium because the filing itself is procedural, but the underlying shareholder vote could involve high-impact decisions for the company and its stock.
Analyst Insight
A smart investor would monitor Transcode Therapeutics' subsequent filings (e.g., DEF 14A, 8-K) for details on the specific matters submitted to a shareholder vote, as these could reveal significant corporate actions or changes impacting the stock.
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- 001-40363 (string) — Commission File Number for Transcode Therapeutics, Inc.
- RNAZ (string) — trading symbol for Transcode Therapeutics, Inc.
- The Nasdaq Capital Market (string) — exchange where RNAZ Common Stock is registered
FAQ
What is the primary purpose of this 8-K filing by Transcode Therapeutics, Inc.?
The primary purpose of this 8-K filing, dated January 8, 2024, is to report the 'Submission of Matters to a Vote of Security Holders,' indicating that the company has submitted or will submit certain issues for a shareholder vote.
What is the ticker symbol and exchange for Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. trades under the symbol RNAZ on The Nasdaq Capital Market, as stated in the filing under 'Securities registered or to be registered pursuant to Section 12(b) of the Act.'
What is the state of incorporation for Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. is incorporated in Delaware, as indicated in the filing under 'State or other jurisdiction of incorporation'.
What specific rule under the Securities Act is mentioned in the 8-K filing?
The filing indicates that it is intended to simultaneously satisfy the filing obligation under 'Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).'
What is the business address and phone number of Transcode Therapeutics, Inc. as listed in the filing?
The business address for Transcode Therapeutics, Inc. is 6 Liberty Square, #2382, Boston, Massachusetts 02109, and their telephone number is (857) 837-3099.
Filing Stats: 705 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-08 16:01:49
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital M
Filing Documents
- tm242383d1_8k.htm (8-K) — 26KB
- 0001104659-24-002225.txt ( ) — 197KB
- rnaz-20240108.xsd (EX-101.SCH) — 3KB
- rnaz-20240108_lab.xml (EX-101.LAB) — 33KB
- rnaz-20240108_pre.xml (EX-101.PRE) — 22KB
- tm242383d1_8k_htm.xml (XML) — 3KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. The following proposals were submitted to the stockholders at the Special Meeting of Stockholders of TransCode Therapeutics, Inc. (the "Company") held on January 8, 2024 (the "Special Meeting"): (i) The approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"), by a ratio of any whole number between 1-for-10 and 1-for-40, the implementation and timing of which shall be subject to the discretion of the Board of Directors (the "Reverse Stock Split Proposal"); and (ii) The approval of an adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding reverse stock split proposal (the "Adjournment Proposal"). The proposals are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on December 18, 2023. The number of shares of Common Stock entitled to vote at the Special Meeting was 25,097,596. The number of shares of Common Stock present or represented by valid proxy at the Special Meeting was 12,472,113. All matters submitted to a vote of the Company's stockholders at the Special Meeting were approved. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: (i) The Reverse Stock Split Proposal: Stockholders approved the Reverse Stock Split Proposal. The results of the voting included 7,081,896 votes for, 5,348,629 votes against and 41,588 votes abstained. There were no broker non-votes regarding this proposal. (ii) The Adjournment Proposal: Stockholders approved the Adjournment Proposal. The results of the voting included 7,426,024 votes for, 4,836,062 votes against and 210,027 votes abstained. There were no broker no
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 TransCode Therapeutics, Inc. By: /s/ Thomas Fitzgerald Thomas Fitzgerald Chief Financial Officer